3,210 Shares in The Cooper Companies, Inc. (NASDAQ:COO) Bought by Brown Advisory Inc.

Brown Advisory Inc. purchased a new stake in shares of The Cooper Companies, Inc. (NASDAQ:COO) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 3,210 shares of the medical device company’s stock, valued at approximately $271,000.

A number of other hedge funds have also recently made changes to their positions in the business. City Holding Co. purchased a new stake in shares of Cooper Companies in the first quarter worth about $34,000. New Age Alpha Advisors LLC purchased a new stake in shares of Cooper Companies in the fourth quarter worth about $38,000. Covestor Ltd lifted its position in shares of Cooper Companies by 35.5% in the fourth quarter. Covestor Ltd now owns 458 shares of the medical device company’s stock worth $42,000 after buying an additional 120 shares in the last quarter. HM Payson & Co. lifted its position in shares of Cooper Companies by 147.4% in the first quarter. HM Payson & Co. now owns 893 shares of the medical device company’s stock worth $75,000 after buying an additional 532 shares in the last quarter. Finally, UMB Bank n.a. lifted its position in shares of Cooper Companies by 16.7% in the first quarter. UMB Bank n.a. now owns 902 shares of the medical device company’s stock worth $76,000 after buying an additional 129 shares in the last quarter. Institutional investors own 24.39% of the company’s stock.

Wall Street Analysts Forecast Growth

COO has been the topic of a number of research analyst reports. Mizuho decreased their target price on Cooper Companies from $105.00 to $90.00 and set an “outperform” rating on the stock in a research report on Wednesday. Piper Sandler reiterated an “overweight” rating and issued a $105.00 target price (down from $115.00) on shares of Cooper Companies in a research report on Friday, May 30th. Wells Fargo & Company decreased their target price on Cooper Companies from $118.00 to $93.00 and set an “overweight” rating on the stock in a research report on Friday, May 30th. Loop Capital set a $100.00 target price on Cooper Companies in a research report on Tuesday, June 17th. Finally, Needham & Company LLC upgraded Cooper Companies from a “hold” rating to a “buy” rating and set a $94.00 price objective on the stock in a research report on Tuesday, June 17th. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, Cooper Companies presently has an average rating of “Moderate Buy” and a consensus price target of $97.20.

Cooper Companies Trading Up 0.7%

COO opened at $72.70 on Thursday. The stock has a market cap of $14.54 billion, a price-to-earnings ratio of 35.29, a P/E/G ratio of 1.76 and a beta of 0.99. The stock’s 50 day moving average price is $74.42 and its 200-day moving average price is $82.30. The Cooper Companies, Inc. has a one year low of $65.00 and a one year high of $112.38. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.23 and a current ratio of 2.10.

Cooper Companies (NASDAQ:COO) last released its earnings results on Thursday, May 29th. The medical device company reported $0.96 EPS for the quarter, beating analysts’ consensus estimates of $0.93 by $0.03. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $995.12 million. Cooper Companies had a return on equity of 9.60% and a net margin of 10.39%. The company’s quarterly revenue was up 6.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.85 earnings per share. On average, equities analysts forecast that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.